As a result, PRKN-expressing cells released an immune-inflammatory secretome rich in IFNs, ISG, and pleiotropic cytokines that stimulated IFNAR1-dependent paracrine activation of effector and cytotoxic CD8+ T cells, promoting their intratumoral accumulation and the inhibition of transgenic and syngeneic tumor growth in vivo. Here, PRKN is linked to neoplasm.